What is the NAFLD Fibrosis Score?
The NAFLD Fibrosis Score (NFS) is a non-invasive clinical scoring system developed by Angulo et al. (2007) to identify patients with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis (stage F3–F4). It uses six routinely measured clinical and laboratory variables, eliminating the need for liver biopsy in many patients.
The NFS has been extensively validated in multiple independent cohorts and is recommended by major hepatology guidelines (AASLD, EASL) as a first-line non-invasive tool for risk stratification in NAFLD patients. It has a high negative predictive value (NPV) of approximately 88–93%, meaning it is particularly good at ruling out advanced fibrosis.
The score uses a dual cutoff system with an indeterminate zone, designed to maximize the utility of the result: patients below the low cutoff can be followed without further invasive workup, while those above the high cutoff should be referred for further evaluation.
NFS Formula
+ 0.094 × BMI (kg/m²)
+ 1.13 × IFG/Diabetes (yes=1, no=0)
+ 0.99 × AST/ALT ratio
- 0.013 × Platelet count (×10&sup9;/L)
- 0.66 × Albumin (g/dL)
Each variable contributes independently to the score. The formula was derived using logistic regression analysis from a cohort of 733 biopsy-proven NAFLD patients and validated in an independent cohort of 253 patients.
Score Interpretation
| NFS Value | Interpretation | Fibrosis Stage | Clinical Action |
|---|---|---|---|
| < -1.455 | Low probability of advanced fibrosis | F0 – F2 | Reassurance; follow-up in primary care; repeat in 2–3 years |
| -1.455 to 0.676 | Indeterminate | Cannot determine | Further evaluation needed: elastography (FibroScan) or liver biopsy |
| > 0.676 | High probability of advanced fibrosis | F3 – F4 | Refer to hepatology; consider liver biopsy; monitor for complications |
Diagnostic Accuracy
| Cutoff | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| < -1.455 (rule out) | 77% | 71% | 52% | 88% |
| > 0.676 (rule in) | 43% | 96% | 90% | 56% |
Fibrosis Staging Diagram
Understanding NAFLD
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease worldwide, affecting an estimated 25–30% of the global adult population. It is defined as the accumulation of fat (steatosis) in the liver in the absence of significant alcohol consumption, viral hepatitis, or other secondary causes of hepatic steatosis.
The NAFLD spectrum includes:
- Simple steatosis (NAFL): Fat accumulation without significant inflammation or fibrosis. Generally benign with low risk of progression.
- Non-Alcoholic Steatohepatitis (NASH): Fat accumulation with hepatocyte injury (ballooning) and inflammation, with or without fibrosis. NASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma.
- NASH cirrhosis: End-stage fibrosis (F4) resulting from NASH. Associated with portal hypertension, liver failure, and increased mortality.
Risk factors for NAFLD include obesity, type 2 diabetes, metabolic syndrome, dyslipidemia, and sedentary lifestyle. The presence and severity of fibrosis is the strongest predictor of adverse liver-related outcomes and overall mortality in NAFLD patients.
Liver Fibrosis Stages (F0–F4)
| Stage | Description | Clinical Significance |
|---|---|---|
| F0 | No fibrosis | Normal liver architecture; no scarring |
| F1 | Mild fibrosis | Perisinusoidal or periportal fibrosis; usually asymptomatic |
| F2 | Moderate fibrosis | Perisinusoidal and portal/periportal fibrosis; still largely asymptomatic |
| F3 | Advanced fibrosis (bridging) | Bridging fibrosis connecting portal tracts; increased risk of progression to cirrhosis |
| F4 | Cirrhosis | Established cirrhosis; risk of decompensation, portal hypertension, HCC, and liver-related mortality |
The NFS is designed to distinguish patients with minimal fibrosis (F0–F2) from those with advanced fibrosis (F3–F4). This distinction is clinically important because advanced fibrosis requires closer monitoring and often specialist hepatology care.
Non-Invasive Assessment Tools
Liver biopsy has traditionally been the gold standard for assessing fibrosis, but it is invasive, costly, carries procedural risk, and is subject to sampling variability. Several non-invasive alternatives are now available:
| Tool | Type | Components | Strengths |
|---|---|---|---|
| NAFLD Fibrosis Score | Blood-based formula | Age, BMI, IFG/DM, AST/ALT, Platelets, Albumin | Free; uses routine labs; high NPV |
| FIB-4 Index | Blood-based formula | Age, AST, ALT, Platelets | Simpler formula; widely used |
| Transient Elastography (FibroScan) | Imaging | Liver stiffness measurement (kPa) | Rapid; operator-independent; high accuracy |
| ELF Score | Blood biomarkers | Hyaluronic acid, PIIINP, TIMP-1 | High accuracy; not routine labs |
| MR Elastography | MRI-based | Liver stiffness via MRI | Highest accuracy; no sampling error |
Current guidelines recommend a sequential approach: start with a simple blood-based score (NFS or FIB-4), and if the result is indeterminate, proceed to elastography. Liver biopsy is reserved for cases where non-invasive tests are inconclusive or when a definitive diagnosis is needed for treatment decisions.
Worked Example
Consider a 50-year-old patient with BMI 28, diabetes, AST 45 U/L, ALT 60 U/L, platelets 200 ×10&sup9;/L, and albumin 4.0 g/dL:
+ 0.037 × 50 = +1.850
+ 0.094 × 28 = +2.632
+ 1.13 × 1 = +1.130
+ 0.99 × (45/60) = +0.743
- 0.013 × 200 = -2.600
- 0.66 × 4.0 = -2.640
NFS = -1.675 + 1.850 + 2.632 + 1.130 + 0.743 - 2.600 - 2.640 = -0.560
A score of -0.560 falls in the Indeterminate zone (-1.455 to 0.676). This patient should undergo further evaluation, such as transient elastography (FibroScan), to better characterize the degree of liver fibrosis.
Frequently Asked Questions
Is the NAFLD Fibrosis Score validated for NASH specifically?
The NFS was developed and validated in patients with biopsy-confirmed NAFLD, which includes both NAFL (simple steatosis) and NASH. It predicts fibrosis severity regardless of whether NASH is present, as fibrosis can occur in both subtypes.
Can I use the NFS in patients with other liver diseases?
The NFS was specifically developed for NAFLD. It should not be used in patients with significant alcohol consumption, viral hepatitis (HBV/HCV), autoimmune hepatitis, or other liver diseases, as the scoring variables may behave differently in these conditions.
What does "indeterminate" mean clinically?
An indeterminate result means the score cannot reliably classify the patient as having or not having advanced fibrosis. Approximately 20–30% of patients fall in this zone. These patients need additional testing — typically liver elastography — to determine their fibrosis stage.
How often should the NFS be recalculated?
For patients with low scores (F0–F2), reassessment every 2–3 years is reasonable, or sooner if clinical circumstances change (e.g., worsening metabolic control, new symptoms). For patients in the indeterminate zone, reassessment after further workup and after any therapeutic interventions is appropriate.
Why are platelets included in the formula?
Platelet count decreases with advancing liver fibrosis and cirrhosis due to several mechanisms: reduced production of thrombopoietin by the damaged liver, splenic sequestration from portal hypertension, and bone marrow suppression. Low platelets are therefore a clinical marker of advanced liver disease.
What is the AST/ALT ratio and why does it matter?
The AST/ALT ratio (also known as the De Ritis ratio) typically shifts in liver disease. In simple NAFLD, ALT is usually higher than AST. As fibrosis progresses, the AST/ALT ratio increases and may exceed 1.0 in cirrhosis. An elevated ratio suggests more advanced disease and contributes positively to the NFS.